title: Association of initial antipsychotic response to clozapine and long-term weight gain.
abstract: OBJECTIVE
  The aim of this study was to test whether the initial antipsychotic response to clozapine is related to subsequent weight change.
  
  
  METHODS
  This study was an 8-year retrospective chart review of 96 hospitalized patients with schizophrenia. Data on monthly weight change, initial clinical response, age, gender, clozapine dose, and concomitant use of mood stabilizers and other antipsychotics were analyzed.
  
  
  RESULTS
  Fifty-five (57.3%) of the patients received clozapine over the entire 8-year period; these subjects experienced an average weight gain of 11.7 kg (SD=1.6). Seventeen of these patients (30.9%) who had a significant initial clinical response (CGI improvement rating of 1 or 2 during the first 14 months) gained significantly more weight (13.8 kg [SD=8.4]) than did the 38 patients without a significant initial response (4.5 kg [SD=12.0]). Multiple linear regression analysis showed significant initial clinical response and lower baseline body mass index were associated with significantly more weight gain.
  
  
  CONCLUSIONS
  The results show that initial antipsychotic response to clozapine is associated with subsequent long-term weight gain as measured over 8 years.
authors.affiliation: Community Medicine Research Center and Institute of Public Health, National Yang-Ming University,155 Li-Nong St., Sec. 2, Shihpai, Taipei 112, Taiwan.
authors.forename: Ya Mei
authors.initials: YM
authors.lastname: Bai
authors.forename: Chao-Cheng
authors.initials: CC
authors.lastname: Lin
authors.forename: Jen-Yeu
authors.initials: JY
authors.lastname: Chen
authors.forename: Chih-Yuan
authors.initials: CY
authors.lastname: Lin
authors.forename: Tung-Ping
authors.initials: TP
authors.lastname: Su
authors.forename: Pesus
authors.initials: P
authors.lastname: Chou
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015992:Body Mass Index; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006760:Hospitalization; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009765:Obesity / Q000139:chemically induced* / Q000175:diagnosis; D011379:Prognosis; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D012008:Recurrence; D012189:Retrospective Studies; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine